Patients

KST-6051 in Patients

Kestrel Therapeutics has begun a Phase 1 study in patients with advanced/metastatic solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC), with KRAS mutations following clearance of the KST-6051 IND by the US Food and Drug Administration.

KST-6051 is a potential best-in-class, oral pan-KRAS inhibitor which is being developed for the treatment of advanced malignancies. KST-6051 is a potent and selective inhibitor of KRAS, with balanced activity against KRAS in the active (GTP-bound) and inactive (GDP-bound) states, that has consistently demonstrated on-target pathway modulation and anti-proliferative activity in several KRAS-dependent cancer cell lines. Once daily, oral administration of KST-6051 has similarly been shown to lead to robust activity at well tolerated doses in multiple human KRAS-dependent tumor models.  KST-6051 has been shown to be well tolerated at relevant doses in multiple species.

Trial thumbnail

KST-6051-101

A First-in-Human Phase 1 Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation [NCT07458347]

Phase I
Recruiting
  • Eligible patients have advanced or metastatic solid tumors with a locally assessed KRAS mutation and have received prior systemic therapy for metastatic disease.
  • The study is currently enrolling patients at multiple clinical trial sites across the United States.
  • Expansion cohorts are planned that will evaluate KST-6051 in specific cohorts of patients with advanced or metastatic solid tumors including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC) at multiple additional sites in the United States and other countries.
  • For more information on the study, please contact Kestrel Therapeutics at 617-612-6810 or [email protected].

ClinicalTrials.gov identifier: NCT07458347

Kestrel Therapeutics is committed to developing innovative, next-generation targeted therapies. At present, no investigational product candidates are available for Expanded Access. The only way to access investigational treatments is through participation in clinical trials, which are specifically designed to rigorously assess their safety and efficacy. Please be advised that our policy regarding Expanded Access is subject to change without prior notice.